行情

AGLE

AGLE

Aeglea Bio
NASDAQ

实时行情|Nasdaq Last Sale

7.90
+0.13
+1.67%
已收盘, 16:34 10/17 EDT
开盘
7.91
昨收
7.77
最高
7.99
最低
7.80
成交量
3.26万
成交额
--
52周最高
10.28
52周最低
5.99
市值
2.28亿
市盈率(TTM)
-3.4291
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

AGLE 新闻

  • 达里奥:全球经济陷入大衰退,令人想起上世纪30年代
  • 环球外汇网官网.2小时前
  • 盘点!英国脱欧究竟对美股和全球股市意味着什么?
  • 环球外汇网官网.2小时前
  • Libra协会回应G7:Libra可与央行数字货币共存
  • 新浪财经综合.2小时前
  • Telegram回应SEC:Gram代币不是证券
  • 新浪财经综合.2小时前

更多

所属板块

生物技术和医学研究
+0.95%
制药与医学研究
+0.61%

热门股票

名称
价格
涨跌幅

AGLE 简况

Aeglea BioTherapeutics, Inc. is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company's product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine. AEB1102 reduces blood arginine levels in nonclinical and oncology clinical studies. AEB3103 targets the degradation of the amino acid cysteine/cystine. AEB2109 targets the degradation of the amino acid methionine. AEB4104 targets the reduction of elevated levels of the amino acid homocystine associated with the IEM classical homocystinuria.
展开

Webull提供Aeglea Bio Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。